V-Go Shown to Have Improved Benefit for Insulin Patients

This study demonstrated that patients treated by Advanced Practitioners experienced improved A1c levels while lowering insulin total daily dose (TDD) after switching to V-Go from MDI of insulin. Patients in this study were evaluated after a mean duration of three and seven months. At three months, the mean change in A1c was -1.1% from the mean baseline of 9.1%, and mean insulin TDD decreased to 58 units per day from a mean baseline of 87 units per day. At seven months, the mean change in A1c was also -1.1%, while the mean insulin TDD was 61 units per day. Change in the mean weight was less than 1 kg at both time points. “For many patients with type 2 diabetes, being able to adhere to an insulin regimen consisting of multiple daily injections is a real challenge as it can be burdensome to daily living and complex,” said Amanda Patricia Wakim, DNP, FNP-BC an endocrinology-focused nurse practitioner in Wheeling, WVA, in a release. “In my practice, V-Go has been well received by patients as it removes the need for multiple injections, is simple to use, and has enabled many of my patients to lower their glucose, use less insulin, and not gain the weight normally seen with intensified insulin therapy.” Valeritas received a nod from FDA to market Valeritas in 2010. V-Go is an all-in-one basal-bolus insulin delivery option for patients and was designed to deliver a continuous preset basal rate of insulin over a 2...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news